4.7 Article

Structural and functional consequences of mitochondrial biogenesis in human adipocytes in vitro

期刊

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
卷 90, 期 12, 页码 6650-6656

出版社

ENDOCRINE SOC
DOI: 10.1210/jc.2005-1024

关键词

-

向作者/读者索取更多资源

Introduction: Mitochondrial biogenesis is a complex process, and several factors and signaling pathways regulate this process in muscle or brown adipocytes. The aim of the study was to explore pathways affecting mitochondrial biogenesis and fatty acid oxidation ( FAO) in human white adipocytes. Methods: Human preadipocytes obtained from liposuction samples were differentiated in vitro. On the 10th day of differentiation, 4 mu M forskolin and 1 mu M peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonist ( pioglitazone, rosiglitazone, or GW 929) or 10 mu M (PPAR gamma) agonist (WY-14,643) were added to the media for 96 h. Quantitative real-time PCR was used to determine gene expression/mitochondrial copy number and C-14- labeled palmitate to measure direct energy dissipation. Results: The treatment of adipocytes with forskolin increased mitochondrial copy number and the expression of genes involved in mitochondrial biogenesis ( PPAR gamma coactivator 1 alpha and transcriptional factor A) and fatty acid oxidation ( PPAR alpha and medium-chain acylcoenzyme A dehydrogenase). The end ( CO2) and intermediate products ( C-14- labeled acid-soluble products) of FAO were also increased after forskolin treatment. PPAR gamma and PPAR alpha agonists increased mitochondrial copy number, uncoupling protein 1, medium-chain acylcoenzyme Adehydrogenase, and carnitine palmitoyltransferase 1, but did not change PPAR alpha, PPAR gamma coactivator 1 alpha, or transcriptional factor A mRNA levels. FAO was higher after rosiglitazone, GW 929, and WY-14,643 but not after pioglitazone treatment. Conclusions: Pharmacological activation of the cAMP or PPAR gamma pathway pushes the white adipocyte down the oxidative continuum. The direct energy-dissipating effects could be significant tools to treat obesity and to improve insulin resistance in type 2 diabetic patients by reduction of fat accumulation in adipocytes or by reprogramming fatty acid metabolism.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据